Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome is characterized by congenital ptosis and posterior fusion of the lumbosacral vertebrae. It has been described in a mother and her two daughters.
Features include: Abnormality of metabolism/homeostasis, Congenital ptosis, and Posterior fusion of lumbosacral vertebrae.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Metabolism | 1 | Abnormality of metabolism/homeostasis |
Eyes |
Biomarker and diagnostic research for posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome.
121 publications have been identified in PubMed for posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome. Research spans Review / Meta-Analysis (69%), Basic Science / Preclinical (7%), and Case Report / Case Series (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 84 | 69% |
Data assembled from 5 of 12 sources · Last updated Sep 21, 2026, 4:55 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1
Congenital ptosis |
Pregnancy and birth | 1 | Congenital ptosis |
Bones and joints | 1 | Posterior fusion of lumbosacral vertebrae |
Laboratory research |
9 |
7% |
Patient case studies | 8 | 7% |
New treatment approaches | 6 | 5% |
Other research | 5 | 4% |
Disease patterns and progression | 5 | 4% |
Testing and diagnosis research | 3 | 2% |
Clinical study results | 1 | 1% |
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Zhu Y (2026). [PMID: 41285585](https://pubmed.ncbi.nlm.nih.gov/41285585/). *Int J Spine Surg*. [Review / Meta-Analysis]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Chan KCA (2026). [PMID: 41810395](https://pubmed.ncbi.nlm.nih.gov/41810395/). *J Spine Surg*. [Review / Meta-Analysis]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Dev Med Child Neurol*. [Review / Meta-Analysis]
Pignataro G (2025). [PMID: 41010942](https://pubmed.ncbi.nlm.nih.gov/41010942/). *Medicina (Kaunas)*. [Review / Meta-Analysis]
Yacoub MR (2025). [PMID: 40747632](https://pubmed.ncbi.nlm.nih.gov/40747632/). *Curr Opin Allergy Clin Immunol*. [Review / Meta-Analysis]
Kaul A (2025). [PMID: 40915300](https://pubmed.ncbi.nlm.nih.gov/40915300/). *Lancet Rheumatol*. [Review / Meta-Analysis]
Maki Y (2025). [PMID: 40130148](https://pubmed.ncbi.nlm.nih.gov/40130148/). *Cureus*. [Case Report / Case Series]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]